Iterum Therapeutics (ITRM) Stock Dips 17.19% This Month As It Gives An Update On The FDA Type A Meeting On Oral Sulopenem

Today on the agenda, the stock market of healthcare company suffers a dip in prices. The value has reached a new price mark of $0.5548. Comparing the monthly statistics, it could be noticed that the company showed negative dynamics. Prices were fluctuating from $0.70 to $0.54. On September 2, Iterum Therapeutics (ITRM) faced a sharp breakout and reached the point of $0.70, however, after an increase now the company suffers volatility. Iterum Therapeutics, a clinical-stage healthcare company focused on developing future generation orally and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company held a Type A meeting with the U.S.Iterum Therapeutics (ITRM) Stock Dips 17.19% This Month As It Gives An Update On The FDA Type A Meeting On Oral Sulopenem Food and Drug Administration (FDA) during the third quarter of 2021 to discuss the steps required for potential resubmission of the New Drug Application (NDA) for sulopenem cefadroxil/probenecid for the treatment of uncomplicated urinary tract infections. The FDA issued a Complete Response Letter (CRL) to the company in July, asking for further evidence to support the approval of oral sulopenem for the treatment of adult women with uUTI.

Miriam Bozini

Finance and Business Reporter